Nosh.bio, a German startup developing highly functional ingredients from fungal biomass for animal-free food products, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership. Nosh.bio will leverage Ginkgo Strain Optimization Services to screen for protein-producing fungi strains with superior sensorial profiles. By leveraging Ginkgo’s ultra-high throughput encapsulated screening capabilities, the program aims to produce a mycoprotein that delivers a rich, savory, and natural meaty taste when used in food products.
Companies developing animal-free protein still face challenges in creating tastier, less processed, and affordable alternative-protein products. Nosh.bio has built a technological platform that uses fungal biomass to create animal-free single-ingredient animal meat alternatives from mycoprotein for human nutrition.
For meat alternatives, red meat — like a juicy steak — remains the most challenging product to develop, and current alternatives contain many ingredients and chemical additives. Nosh.bio aims to leverage its highly efficient, sustainable, and cost-effective production process to create a single-ingredient animal-free product that tastes and feels just like red meat while being healthier than an animal product.
To enable this advanced alt-protein product, Ginkgo aims to discover and deliver a strain of fungi with higher native proteins involved in achieving the rich meat taste, juiciness, and color that Nosh.bio is seeking. To do so, Ginkgo plans to execute a mutagenesis and screening campaign with its proprietary encapsulation and screening technology (EncapS), which can make it possible to search through up to 1 million strain variants in a single run and select the best-performing candidates for further development. Using such an improved strain can help Nosh.bio develops a mycoprotein that is superior in taste, color, performance, and nutrition.
“Nosh.bio is eager to enable the transition from animal-based to animal-free products. Our affordable, high-quality plant-based ingredients can build a product that’s even closer to meat in taste and texture than alt-protein options currently on the market,” said Tim Fronzek, CEO and Co-Founder of Nosh.bio. “What really excites us about partnering with Ginkgo is their accelerated screening technology that can help us pinpoint and develop a super ‘meaty’ mycoprotein.”
“We’re thrilled to partner with Nosh.bio and help level up the alt-meat protein industry to deliver sustainable products that taste closer to real meat than ever before,” said Kalpesh Parekh, Vice President of Business Development at Ginkgo Bioworks. “Our proprietary encapsulation and screening technology can expeditiously deliver valuable insights that enable our partners to optimize their R&D efforts and overall product.”
To learn more about Ginkgo Strain Optimization Services, please visit https://www.ginkgobioworks.com/offerings/strain-optimization-services/.
About Ginkgo Bioworks
Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo’s biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and concentricbyginkgo.com, read our blog, or follow us on social media channels such as X (formerly known as Twitter) (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks and @ConcentricByGinkgo), Threads (@GinkgoBioworks) or LinkedIn.
About Nosh.bio
Nosh.bio GmbH is a Berlin-based startup founded with the company builder EVIG in February 2022, and backed by Earlybird in 2023. Nosh.bio’s goal is to transform the food industry in a way that it is no longer harmful – neither to nature nor to animals, nor to people. For this purpose, animal-free proteins are to become the main protein source in human nutrition. Nosh.bio develops a technological platform to produce a new class of highly functional food ingredients. The structuring ingredients are clean-label, healthy, nutritious, and tasty. The technology is efficient, allowing ingredients to be produced at price parity with animal products. As a business partner, Nosh.bio wants to help the manufacturers of animal-free products to compensate for the disadvantages of animal products in terms of taste, texture, and price so that they reach the mass market.
More information on www.nosh.bio and LinkedIn
Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo’s cell programming platform. These forward-looking statements generally are identified by the words “believe,” “can,” “project,” “potential,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) volatility in the price of Ginkgo’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo’s business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) our ability to realize the expected benefits of merger and acquisition transactions, (vii) the outcome of any legal proceedings against Ginkgo, including as a result of recent acquisitions, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (x) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Ginkgo’s quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 9, 2023 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.
NOSH.BIO CONTACT:
[email protected]
GINKGO BIOWORKS INVESTOR CONTACT:
[email protected]
SOURCE: Ginkgo Bioworks
